Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on October 14, 2009
JNCI Journal of the National Cancer Institute 2009 101(21):1439-1441; doi:10.1093/jnci/djp399
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
101/21/1439    most recent
djp399v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tuma, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tuma, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2009.

NEWS

Progression-Free Survival Remains Debatable Endpoint in Cancer Trials

Rabiya Tuma

The first 150 words of the full text of this article appear below.

In recent years the U.S. Food and Drug Administration has approved cancer therapies on the basis of improved progression-free survival (PFS), including several drugs for the treatment of metastatic kidney cancer. Clinicians who treat kidney cancer patients are convinced that the agency made the right move, and some even contend that overall survival (OS) is no longer a useful endpoint in this disease setting.

However, despite some support for the use of PFS in one disease setting, its value as a standard endpoint for clinical trials remains a point of debate in oncology as a whole. Some experts argue that OS is the only time-to-event endpoint that shows true benefit to patients, whereas others think that PFS should be accepted as long as the trials are carried out according to rigorous standards. To hash out some of those issues, academic and industry statisticians gathered Oct. 7–9 for the Progression-Free Survival . . . [Full Text of this Article]

The Case for PFS

The Debate

Building Better Consensus


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?